Early Access — free while we kick the tires
EdgarHawk

Patil Neena M

EVP & Chief Legal Officer

Officer
2 filings analyzed · 1 company · Latest 2026-03-02

Companies

Company Buys Sells Direction
Jazz Pharmaceuticals plc JAZZ 0 19 Net selling

Activity

March 2026
high
Sell
55,600 shares
$10,650,482
Significance 7/10

Chief Legal Officer Neena M Patil sold 55,600 shares of JAZZ for $10,650,482.29 across 11 transactions

Patil, EVP & Chief Legal Officer, executed 11 separate sales totaling 55,600 shares for $10,650,482.29 on 2026-02-26, reducing her holdings by 48.6% from 114,418 to 58,818 shares. The blended average price of $191.56 is 0.6% above the current price of $190.46 and 2.8% below the 52-week high of $196.83, indicating execution near peak valuation. Her cross-ticker track record shows 50.00% well-timed rate on prior sells (1 of 2 sales preceded declines), and at JAZZ specifically, 1 of 2 prior sells were well-timed at the 90-day mark—most recently a February 2025 sale that preceded a 26.1% decline over 90 days. Against this backdrop, the substantial reduction in her equity stake merits investor attention, particularly given the company was unprofitable over its most recent full fiscal year despite $1.1B quarterly revenue and 4.9% annual growth.

March 2025
low
Sell
3,800 shares
$550,506
Significance 4/10

Chief Legal Officer Neena M Patil sold 3,800 shares of JAZZ at $144.87 for $550,506.00; holds 51,614 post-sale.

Patil sold 3,800 shares at $144.87, realizing $550,506.00 and reducing her holdings by 6.9% to 51,614 shares. The sale occurred near the 52-week high of $144.17, with the stock currently trading at $140.22, suggesting the execution was well-positioned within recent price range. Examining her prior transaction at JAZZ (a sale on 2024-05-03), that trade failed to precede a decline—the stock returned +4.3% over 90 days afterward—indicating no historical pattern of well-timed exits at this ticker. The company maintains solid fundamentals with $1.1B quarterly revenue, $215.1M net income, and a P/E of 13.99, offering no obvious distress signal to explain the sale as discretionary avoidance.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access